-
Product Insights
NewNet Present Value Model: Purple Biotech Ltd’s CM-24
Empower your strategies with our Net Present Value Model: Purple Biotech Ltd's CM-24 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
Likelihood of Approval Analysis for Kaposi Sarcoma
Overview How likely is it that the drugs in Kaposi Sarcoma will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Kaposi Sarcoma Overview Kaposi's sarcoma is a cancer that causes patches of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NT-219 in Recurrent Head And Neck Squamous Cell Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NT-219 in Recurrent Head And Neck Squamous Cell Carcinoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. NT-219 in Recurrent Head And Neck...
-
Product Insights
Likelihood of Approval Analysis for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)
Overview How likely is it that the drugs in Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Overview Idiopathic...
-
Product Insights
Likelihood of Approval Analysis for Thrombocytopenia
Overview How likely is it that the drugs in Thrombocytopenia will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Thrombocytopenia Overview Thrombocytopenia refers to a lower than normal platelet count in the...
-
Product Insights
Likelihood of Approval Analysis for Gram-Positive Bacterial Infections
Overview How likely is it that the drugs in Gram-Positive Bacterial Infections will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Gram-Positive Bacterial Infections Overview Gram-positive bacterial infections are caused by bacteria...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PT-217 in Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PT-217 in Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PT-217 in Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET) Drug Details: PT-217 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NT-219 in Breast Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NT-219 in Breast Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. NT-219 in Breast Cancer Drug Details: NT-219 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NT-219 in Pancreatic Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NT-219 in Pancreatic Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. NT-219 in Pancreatic Cancer Drug Details: NT-219 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NT-219 in Metastatic Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NT-219 in Metastatic Colorectal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. NT-219 in Metastatic Colorectal Cancer Drug Details: NT-219 is under development...